A pproximately 75 patients at Sunnybrook & Women's College Health Sciences Centre (S&WCHSC) undergo peritoneal dialysis (PD) through the Home Dialysis Program. An increasing proportion of these patients are started on continuous cycling peritoneal dialysis (CCPD). Peritoneal dialysis therapy increases a patient's risk of developing peritonitis, which occurs at an average incidence of 1 to 2 episodes per patient per year and is associated with mortality rates as high as 10% (1) . Gram-positive peritonitis involving Staphylococcus aureus or Streptococcus species is common. Gram-negative pathogens, such as Escherichia coli and Pseudomonas aeruginosa, are associated with increased morbidity and late complications in PD patients (2, 3) .
Previously, cefazolin and tobramycin were routinely used as initial empirical antibiotic treatment of bacterial peritonitis in PD patients at S&WCHSC. Aminoglycoside therapy contributes to further decline of residual renal function in PD patients (4) . Although a recent study did not detect a similar effect of aminoglycosides on residual renal function (5) , significantly more patients in the aminoglycoside-treated group were using automated PD, a dialysis modality that may preserve residual renal function and thereby confound study results. Preserving residual renal function in PD patients reduces morbidity and mortality (6) . Accordingly, the International Society for therapy within 14 days before the study day, required the use of Nutrineal (Baxter Corp. Mississauga, Ontario, Canada) (amino acid) solution, had impaired gut absorption of oral agents, had documented hypersensitivity to ciprofloxacin, or were less than 18 years of age. The Ethics Review Board at our institution approved the study protocol and each patient gave written informed consent.
DRUG ADMINISTRATION AND SAMPLE COLLECTION
Patients on CCPD normally use an automated cycler overnight for a number of short-dwell exchanges combined with a long dwell or "dry" dwell in the daytime. For the purposes of this study, the overnight short-dwell exchanges and the daytime long dwell were reversed.
Patients received ciprofloxacin 750 mg orally (Bayer Inc., Toronto, Ontario, Canada) at the hospital on the morning of study day 1 and subsequently underwent a standardized 12-hour period of shortdwell exchanges. The patient then received a second 750 mg ciprofloxacin tablet orally before returning home for an overnight long dwell. On the morning of study day 2, the patient returned to the hospital and a final blood sample was obtained by venipuncture. The dialysate from the overnight long dwell was drained into a drain bag, from which a final end-ofdwell dialysate sample was collected. Instructions for resuming the usual CCPD schedule were provided to the patient on an individualized basis by the home dialysis nurse and/or nephrologist. The total time of the study was 24 hours. All doses of oral ciprofloxacin were given 2 hours after or 1 hour before any antacid or cation products.
BLOOD AND DIALYSATE SAMPLING
Prior to the first ciprofloxacin dose, an Angiocath [Becton, Dickinson & Co. (BD), Franklin Lakes, New Jersey, USA] was inserted into the patient's antecubital vein. The Angiocath was then connected to a three-way stopcock (BD) that linked with a prn adaptor (BD) for drawing blood samples and an intravenous bag of normal saline (Baxter Corp., Toronto, Ontario, Canada) set to run at a slow rate of 0.1 mL/ minute.
A baseline blood sample was taken at time zero (0 hour) immediately after the first ciprofloxacin dose. Patients then started CCPD on the automatic cycler machine (Baxter HomeChoice Automated PD System; Baxter Healthcare, Deerfield, Illinois, USA) for 12 hours according to their usual prescription. The CCPD machine was programmed to ensure that patients received their individual requirements of Peritoneal Dialysis (ISPD) recommends the use of cefazolin and ceftazidime for empirical treatment of peritonitis (7) .
Since ceftazidime overuse in institutions has been associated with the emergence of problematic bacteria (8) [e.g., Enterococci, methicillin-resistant Staphylococcus aureus (MRSA), extended spectrum beta-lactamase-producing P. aeruginosa, other gramnegatives], the antimicrobial subcommittee at S&WCHSC proposed ciprofloxacin as an alternative to ceftazidime for gram-negative coverage in the empirical treatment of PD-related peritonitis. Oral ciprofloxacin is convenient for patients and less expensive than intravenous ceftazidime.
Oral ciprofloxacin, in doses ranging from 250 mg twice daily to 2 g daily, has been investigated for the treatment of peritonitis in patients on continuous ambulatory peritoneal dialysis (CAPD) (9) . Nevertheless, controversy persists with respect to the efficacy and toxicity of ciprofloxacin in this setting. Furthermore, adequate data on the pharmacokinetics of ciprofloxacin in patients receiving CCPD are lacking. Since the rapid automated dialysate exchanges used in CCPD affect peritoneal drug clearance (1), a pharmacokinetic study of oral ciprofloxacin conducted specifically in CCPD patients is required to optimize dosing guidelines for the empirical management of CCPD-related peritonitis.
The objectives of this study were (1) to determine specific pharmacokinetic parameters [maximum serum concentration (C max ), time to maximum serum concentration (t max ), area under the concentrationtime curve (AUC)] of oral ciprofloxacin in CCPD patients, (2) to compare ciprofloxacin levels obtained in blood (C max and AUC) and dialysate with minimum inhibitory concentrations (MIC) of typical gram-negative bacterial pathogens associated with peritonitis, and (3) to establish a guideline for oral ciprofloxacin dosing in the empirical treatment of CCPD-related peritonitis.
METHODS

PATIENT SELECTION
Patients from the Home Dialysis Program at S&WCHSC were included in the study if they had been stabilized on CCPD for at least 1 month and had a Kt/V greater than 2.2, where Kt is the urea elimination rate and V represents volume of urea distribution. Study subjects were screened via patient charts and/or physical examination by a nephrologist to rule out signs and symptoms of a current peritonitis infection. Patients were excluded from the study if they had experienced an episode of peritonitis within 4 weeks before the study day, had received antibiotic
total dialysate volume, fill volume, and last fill volume standardized over 12 hours during the first study day in the hospital. Based on these parameters, the CCPD machine automatically calculated the number of cycles to be performed during the 12 hours of the day and the estimated time per cycle for the patient. During this 12-hour period, serial blood samples and end-of-dwell dialysate samples were collected. Dialysate samples were collected at the end of each dwell using a sample port directly on the automatic cycler machine. In order to obtain a dialysate sample that was representative of the peritoneal concentration, a 15-mL volume of dialysate fluid was extruded through the sample port before collecting the 10-mL dialysate sample. Blood samples (10 mL) were collected from the prn adaptor of the patient's intravenous catheter at times 0, 0.25, 0.5, 0.75, 1, 1.5, 2.5, 4.0, 5.5, 8.5, 11.5, and 12 hours. Approximately 2 mL was withdrawn from the prn adaptor into a 3-mL syringe (BD) and discarded before the study sample was collected into a 10-mL syringe (BD) and immediately transferred into a red-topped Vacutainer tube (BD). Using a 20-mL syringe, approximately 10 mL of normal saline was flushed through the prn adaptor to prevent clotting in the three-way stopcock and the Angiocath. Blood samples were placed in an ice bath and centrifuged within 3 hours of collection. Serum was transferred to a labeled polypropylene tube (Sarstedt Inc., Newton, North Carolina, USA) and stored frozen at -20°C until assayed. Dialysis dwell cycles, times and volumes of dialysate fills and drains, dialysate sample collection times, and ultrafiltration volumes were recorded for each patient.
SAMPLE SIZE CALCULATION
This study was designed to estimate the mean amount of ciprofloxacin cleared by PD and to establish a 90% confidence interval about that value such that the width was less than ±20%. This assumed an intersubject variability (CV%) of 40%. Using α = 0.05, β = 0.2, and standard sample size equations for parametric data, it was estimated that 10 patients were required (10) . CIPROFLOXACIN 
ASSAY
The concentration of quinolones in plasma has previously been measured (11) . Our current assay for ciprofloxacin improves on this method, with a much lower limit of quantification, and is similar to other reverse-phase paired-ion methods (12, 13 ).
An isocratic acidic mobile phase containing a counter ion of 0.005 mol/L tetrabutylammonium hydrogen sulfate (Sigma Chemical Company, St. Louis, Missouri, USA) and 10% acetonitrile (EM Science, Gibbstown, New Jersey, USA) on a 5-µm -25-cm reverse-phase C 18 column (Ultrasphere; Beckman Coulter, Mississauga, Ontario, Canada) with fluorescence detection (λ ex = 282 nm, λ em = 242 nm) was used.
Extraction from 0.2 mL of plasma was accomplished by precipitation of plasma proteins with 0.5 mL of acetonitrile and back extraction with 1 mL of chloroform (EM Science). A portion of the upper aqueous layer (50 µL of a total final volume of approximately 150 µL) was injected into the HPLC system. Chromatograms were recorded on a computer using ChromQuest software (ThermoQuest, San Jose, California, USA). Standards for serum were prepared, ranging in concentration from 50 to 15 000 ng/mL. All samples and standards were prepared in duplicate.
Analysis of dialysate samples was completed using an identical chromatographic system, isocratic acidic mobile phase, and fluorescence detector. However, ciprofloxacin was not extracted from the sample. Rather, 50-µL volumes of each sample were directly injected into the chromatographic system. Chromatograms were recorded on a computer using the ChromQuest software (ThermoQuest).
DATA AND STATISTICAL ANALYSES
Microsoft Excel for Windows 2000 was used to record and tabulate the data collected. A serum concentration-time curve graph was plotted for each patient. The C max and t max were determined directly from the serum concentration-time curve as the highest observed concentration (C max ) and the time at which this concentration occurred (t max ). The AUC was determined using the trapezoidal rule to the last nonzero time point. The AUC from the last non-zero time point was determined by the pharmacokinetic method, concentration/k, where k is the elimination rate constant determined from log-linear regression of the terminal phase of the concentration-time profile.
Peritoneal clearance (Cl PD ) was calculated, based on the cumulative amount recovered in dialysate during each dwell and the AUC for that dialysis interval (τ), according the equation
where C PC represents the concentration of drug recovered in the dialysate sample and V PC represents the volume of dialysate drained from the peritoneal cavity (14) . Peritoneal clearance was then expressed SEPTEMBER 2004 -VOL. 24, NO. 5 PDI as a percentage of the total body clearance (TBC), which was calculated using the equation
where F represents oral bioavailability and was assumed to be 80% (14) . Specific oral bioavailability data were not available for our study population. Means, standard deviations, standard errors of the means (SEM), and 90% confidence intervals were calculated for C max , t max , AUC, (k), apparent TBC, and Cl PD . The plasma AUC:MIC ratio for typical gramnegative bacterial pathogens was determined for each study patient, and the percentage of patients who had a plasma AUC:MIC ≥ 125 was calculated (15) . The end-of-dwell dialysate concentration-to-MIC ratio was determined as a representation of dialysate peak-to-MIC ratio for typical gram-negative bacterial pathogens for each study patient, and the percentage of patients who had an end-of-dwell dialysate concentration-to-MIC ratio ≥ 10 was calculated (16) .
RESULTS
Eight patients were enrolled in the study between January and May 2002. Their mean Kt/V was 2.6, and the patients had been on PD for at least 12 months at the time of the study. Patient demographics are shown in Table 1 .
PLASMA STANDARDS
The lowest standard that was run in this analysis of 104 plasma samples had a concentration of 50 ng/mL. However, in this sample set, 3 samples were observed to have estimated concentrations between 7 and 50 ng/mL. The observed CV of duplicate analysis was 0.17%, 1.52%, and 15.1%. For all 88 non-zero concentrations, the observed CV of duplicate analysis averaged 2.09% (range 0.015% -15.1%, median 1.65%).
We have also completed a comparison of a concentration-time profile from a single patient over 12 hours with this method using LC-fluorescence versus LC-MS-MS detection (API III Plus; Sciex, a division of MDS Health Group, Toronto, Ontario, Canada). We obtained a correlation (MS vs fluorescence) with an r value of 0.9987, and concentration-time profiles were virtually superimposable.
Since metabolites were not quantified in this study, a gradient was not necessary, as we are confident that the metabolite eluted into the solvent front and was separated from ciprofloxacin but could not be quantified.
DIALYSATE ANALYSIS
The lowest standard that we ran in our most recent analysis of 64 non-zero dialysate samples is 62.5 ng/mL. However, in this sample set, 2 samples were observed to have estimated concentrations of 24 ng/mL and 54 ng/mL. The observed CV of duplicate analysis for each sample was 0.40% and 2.85% respectively. For all 64 non-zero concentrations in this analysis, the observed CV of duplicate analysis averaged 1.08% (range 0.027% -4.93%, median 0.84%).
SERUM DATA
The mean ± SEM ciprofloxacin peak serum concentration was 2.7 ± 0.5 mg/L, which occurred 1.6 ± 0.1 hours after the first dose was administered (Figure 1) . The mean serum elimination half-life of ciprofloxacin was 10.1 ± 1.2 hours. The mean serum concentration obtained after the overnight long dwell was 2.29 ± 0.55 mg/L, which occurred 11.9 ± 0.3 hours after the second dose.
DIALYSATE DATA
Since dialysate samples were collected at the end of each dwell, each point on the end-of-dwell dialysate concentration versus time curve in Figure 1 was considered separately. The maximum mean end-ofdwell dialysate concentration was 0.71 ± 0.10 mg/L, which occurred 4.4 ± 0.1 hours after the first dose (Figure 1) . The mean end-of-dwell dialysate concentration after the overnight long dwell was 1.82 ± 0.25 mg/L, occurring at 11.7 ± 0.2 hours after the second dose. The concentration observed after the second dose was 2.5 times greater than the maximum concentration observed after the first dose, and almost 6 times higher than the last concentration observed after the first dose. Although this may be due, in part, to accumulation with multiple doses, it is more likely due to the longer length of the overnight dwell.
CIPROFLOXACIN TOLERABILITY
Ciprofloxacin was well tolerated. Patient 1, who has non-insulin-dependent diabetes mellitus, experienced general malaise on the morning of study day 2 related to inadequate blood sugar control. Patient 4 complained of one episode of nausea and vomiting upon returning home on the night of study day 1.
CONCENTRATIONS IN RELATION TO MIC
As shown in Figure 1 , following a single oral dose of 750 mg ciprofloxacin, serum concentrations of ciprofloxacin remained above the MIC for E. coli, Klebsiella spp, and P. aeruginosa. The population-based MICs refer to concentrations at which at least 90% of visible bacterial growth is inhibited (16) . Mean endof-dwell dialysate concentrations of ciprofloxacin following a single oral dose of 750 mg remained above the MICs for E. coli and Klebsiella spp, but not above the MIC for P. aeruginosa.
An AUC:MIC of at least 125 is a fluoroquinolone pharmacodynamics parameter associated with an 80% clinical and microbiological cure rate in infections due to aerobic gram-negative bacilli (15) . All patients in our study had a serum AUC:MIC greater than 125 for E. coli and Klebsiella spp; however, only 2 patients achieved a serum AUC:MIC of at least 125 for P. aeruginosa (Table 2) .
Optimal bactericidal activity for antibiotics that exhibit concentration-dependent killing is generally represented by a peak concentration-to-MIC ratio of 10 (16), which was obtained for E. coli after the first dose (Table 3) . After the second ciprofloxacin dose, optimal peak end-of-dwell dialysate concentration-to-MIC ratios were obtained for both E. coli and Klebsiella spp but not for P. aeruginosa.
PERITONEAL CLEARANCE (Cl PD )
After the first oral dose of 750 mg ciprofloxacin, the mean ± SEM amount of ciprofloxacin cleared during the first dosing interval was 7.0 ± 0.5 mg, and the mean calculated Cl PD was 306 ± 12.6 mL/hour. Peritoneal clearance represented 1.2% ± 0.1% of the mean calculated TBC.
DISCUSSION
Our results indicate a clear role for oral ciprofloxacin in several clinical situations. Oral ciprofloxacin, 750 mg twice daily, achieved concentrations in the end-of-dwell dialysate that were sufficiently greater than the MICs for typical gram-negative bacteria, such as E. coli and Klebsiella spp. Although this regimen may be suboptimal for antipseudomonal activity, some bacterial killing of P. aeruginosa still occurs when the drug concentration exceeds the MIC. Thus, oral ciprofloxacin is an appropriate agent for initial empirical management of peritonitis prior to the availability of culture and sensitivity data.
In addition, our study supports the continued use of ciprofloxacin, 750 mg orally every 12 hours, for the treatment of peritonitis caused by E. coli or Klebsiella spp. However, this regimen is not recommended for the treatment of a documented P. aeruginosa peritonitis infection, in which case, traditional therapy with ceftazidime or other antipseudomonal agents may be required. Normally, drugs distribute well across the peritoneal membrane. In the setting of peritonitis, the peritoneal membrane is inflamed. The degree to which an inflamed peritoneal membrane may affect dialysate concentration of ciprofloxacin is not known. Oral ciprofloxacin at doses of 750 mg or greater administered every 12 hours for the treatment of peritonitis due to P. aeruginosa requires clinical investigation. The observed mean serum elimination half-life of ciprofloxacin in the study population was approximately 10 hours, which approaches the 12-hour dosing interval. According to the mean accumulation factor, as the elimination half-life approaches the dosing interval, the drug concentration at steady state approaches twice that of the drug concentration after a single dose (14) . Since concentration is directly proportional to the AUC, a steady state concentration that is two times greater than the concentration after the first dose would produce a serum AUC:MIC well above the target value of 125 for P. aeruginosa. Furthermore, end-of-dwell dialysate concentration-to-MIC ratios would be greater. In this case, ciprofloxacin 750 mg orally every 12 hours may be appropriate for the management of systemic infections caused by P. aeruginosa in CCPD patients. However, this hypothesis requires investigation.
The data collected from all 8 patients in our study remained within the statistical parameters initially used to calculate a target sample size of 10 patients. The observed width of the confidence interval about the mean for ciprofloxacin recovered in dialysate was ±14%, and thus the observed confidence interval is narrower than the original design intended.
Study limitations include the various numbers of CCPD cycles for each patient during the standardized 12-hour period. Nevertheless, a trend was not observed between the number of CCPD cycles and the amount recovered in the dialysate. Also, serum samples were obtained at predetermined times rather than at mid-dwell or end-of-dwell times because each patient's CCPD regimen was standardized to 12 hours rather than to the number of cycles. Future studies may characterize drug distribution between each endof-dwell sample point.
Several studies previously looked at ciprofloxacin pharmacokinetics in CAPD patients (17) (18) (19) and reported a negligible effect of PD on ciprofloxacin clearance (< 4%), as well as a longer elimination half-life. Plasma and dialysate kinetics in patients with peritonitis were not significantly different from those with- out infection when investigated using a multiple-dose pharmacokinetic study design (17) . Ciprofloxacin levels recovered in the dialysate after the administration of a single 750-mg oral dose were above the MIC for most aerobic gram-negative bacilli during the 24-hour dialysis period, thereby supporting the role of oral ciprofloxacin in the treatment of PD-related peritonitis (18) . Our study extends the evidence for ciprofloxacin to patients undergoing CCPD.
Troidle et al. (20) found that intraperitoneal cefazolin (2 g once daily) and oral ciprofloxacin (500 mg twice daily) as empirical therapy for peritonitis was effective in 35 of 40 patients on CCPD. However, one of the 4 study patients who had gram-negative peritonitis failed treatment for P. aeruginosa peritonitis (20) . Similarly, the results of our study do not support the use of ciprofloxacin at 750 mg twice daily for treating a documented P. aeruginosa peritonitis. However, the use of ciprofloxacin 750 mg twice daily as empirical therapy for gram-negative peritonitis in this patient population would appropriately restrict ceftazidime usage to documented P. aeruginosa infections and minimize the undesirable complications of ceftazidime overuse.
